Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
CGNSF COGNETIVITY NEUROSCIENCES LTD
0.218-0.010-4.39%
Close
02/03 16:00 ET
High
0.218
Open
0.218
Turnover
1.35K
Low
0.214
Pre Close
0.228
Volume
6.25K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
UK-Based Psychedelics Ancillary Business Wraps Up $3M Funding Round
A tech company responsible for creating a clinical testing platform that uses AI and machine learning for the detection of earliest cognitive impairment signs, Cognetivity Neurosciences Ltd. (OTCQB:CG
Ketamine One Teams Up With Cognetivity Neurosciences To Study PTSD, Depression
Ketamine One, a Canada-based health and wellness company focused on treatments for mental health, is teaming up with Cognetivity Neurosciences (OTC:CGNSF) for a collaborative study on treatments for P
Press Release: Cognetivity Neurosciences Announces Securities Issuances
Cognetivity Neurosciences Announces Securities Issuances Canada NewsWire VANCOUVER, BC, Nov. 5, 2021 VANCOUVER, BC, Nov. 5, 2021 /CNW/ - The Company has issued 220,000 common shares at
Press Release: Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update
Cognetivity Neurosciences Wins Health & Technology Awards and Announces Corporate Update Canada NewsWire VANCOUVER, BC, Oct. 13, 2021 Company's technology awarded 'Best use of AI an
No More
Company Overview
More
Cognetivity Neurosciences Ltd. operates as a technology company. The firm engages in the development of platforms for medical uses such as early detection and monitoring of cognitive impairment in neurodegenerative diseases. It uses visual stimulus based diagnostic test and artificial intelligence tools, such as Integrated Cognitive Assessment. The company was founded by Dr. Sina Habibi and Dr. Seyed-Mahdi Khaligh-Razavi on December 11, 2015 and is headquartered in Vancouver, Canada.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet